###### Significance of this study

What is already known about this subject?
=========================================

Immune system dysfunction in people with diabetes is thought to make these individuals more liable to infections. Certain infections appear more prevalent in patients with diabetes. 

What are the new findings? 
===========================

This study extends the current state of knowledge about the association between diabetes and the incidence of common infections. Furthermore, gaps within the literature are identified. 

How might these results change the focus of research or clinical practice? 
===========================================================================

The knowledge generated from this review will help further inform physicians and researchers and aid in a better understanding of the magnitude and precision of the association between diabetes and developing infections.

Introduction {#s1}
============

The International Diabetes Federation estimates that there were almost 400 million people living with diabetes throughout the world in 2014. The prevalence of diabetes is expected to increase to more than 590 million people by the year 2035.[@R1] Well-known complications of diabetes include both microvascular (retinopathy, neuropathy, nephropathy) and macrovascular (coronary heart disease, cerebrovascular disease, and peripheral vascular disease)[@R2]; however, there are numerous lesser known complications including effects on immunity.[@R3] Immune system dysfunction in people with diabetes may be mediated through impaired migration, phagocytosis, intracellular killing, and chemotaxis.[@R4] Indeed, several studies have suggested that people with diabetes are at an increased risk of infection-related mortality[@R9]; however, not all studies support such an association.[@R11] Furthermore, patients with diabetes tend to be hospitalized for infections more frequently than those without.[@R3]

Although previous studies suggest that certain infections are more prevalent in patients with diabetes,[@R13] there is still lack of substantive and consistent evidence regarding whether diabetes is associated with an increase in the incidence of infections.[@R14] To our knowledge, there has not been an attempt to thoroughly summarize the existing evidence of the association between diabetes and incident infections and quantify the association across a spectrum of infectious diseases. Therefore, we conducted a systematic review and meta-analysis to provide a comprehensive summary of the current state of the evidence surrounding the relationship between diabetes and incident infections.

Research design and methods {#s2}
===========================

Study design {#s2a}
------------

This systematic review was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) and MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines during all stages of design, implementation and reporting.[@R17]

Eligibility criteria {#s2b}
--------------------

This review included observational studies assessing the association between diabetes and incident infections. Study designs that were eligible for inclusion were cohort studies (CS), case--control studies (CCS), nested case--control or case--cohort studies. Other study designs such as systematic reviews and meta-analyses, case series, case reports, or cross-sectional studies were excluded from this review as the temporality between exposure and outcome is uncertain. Studies were included if the population studied was 18 years and older. We excluded younger population due to the fact that the immune system of this category is still developing, and this could affect our outcome of interest. Studies were required to report the number of incident infections in patients with diabetes and in patients without diabetes. Classification of the type of diabetes was based on the definition used in each study. Studies including any type of diabetes were eligible including type 1 diabetes, type 2 diabetes, gestational diabetes, other, and unspecified diabetes. We categorized outcomes into the following categories: infection (not specified), respiratory tract infections (RTI; upper and lower), genitourinary tract infections, skin and soft tissue infections (SSTI), gastrointestinal infections, head and neck infections (H&NI), viral infections, and any other infections not classified here. 

Data sources and searches {#s2c}
-------------------------

The search strategy was carried out in collaboration with a research librarian experienced in systematic reviews. We searched the following biomedical databases from inception to December 31, 2013: PubMed, EMBASE, the Cochrane Library, International Pharmaceutical Science, and Web of Science. MeSH and free-text terms were used to search PubMed. EMTREE and free-text terms were used to search EMBASE. In searching the Cochrane Library, MeSH terms were used as well as free-text terms to capture items not indexed with MeSH. The remaining databases were searched using free-text terms. The search was restricted to English language. See A[ppendix A](#SP1){ref-type="supplementary-material"} for a sample of the search strategy.
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###### Supplementary Appendix 1

Study selection {#s2d}
---------------

Two independent reviewers (WAA, AR) screened titles and abstracts, and then went on to screen full-text manuscripts. Identification of relevant studies was through the use of a standardized study eligibility/relevance form. Discrepancies were resolved by consensus. If consensus was not achieved, a third reviewer was consulted.

Data extraction and quality assessment {#s2e}
--------------------------------------

Data were extracted by one reviewer onto a predesigned form that included first author, contact details, journal citation, year of publication, study design, funding, sample size, data set used, study location and duration, duration of follow-up, study population characteristics, statistical analysis used, the study-specific measure of association, and type of exposure. Two independent reviewers (JD, PH) verified the accuracy of the extracted data. The quality of the observational studies was appraised through the Newcastle-Ottawa Quality Assessment Scale (NOS)[@R19] according to the procedures recommended in the Cochrane Handbook of Systematic Reviews. One author assessed the methodological quality of all the selected studies. The NOS includes a 'star system' in which a study is judged on three domains: selection of the study groups (four items); comparability of the groups (two items); and ascertainment of either the exposure or outcome (three items). If any item of the NOS (eg, case definition or exposure ascertainment) is not reported, a zero score is given. Studies score one star for each area addressed, with scores between 0 and 9 (the highest level of quality). We classified study quality according to the study score into poor (score 0--3), moderate (score 4--6) and high quality (score 7--9).

Data synthesis and analysis {#s2f}
---------------------------

Characteristics of included studies were described and stratified by study design. DerSimonian-Laird random effects models were used to pool results from included studies for each outcome within CS and CCS. Furthermore, unadjusted and adjusted results were pooled separately. Adjusted results were pooled from measures of association reported from the most adjusted statistical model from each study (covariates used in the models varied across included study and are reported in [Appendix C](#SP2){ref-type="supplementary-material"}). For dichotomous data, the results are expressed as OR with corresponding 95% CI. For continuous data, the results are expressed as weighted mean difference (WMD) with 95% CIs, or as standardized WMD if applicable (ie, outcomes are conceptually the same but measured differently).
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###### Supplementary Appendix 2

As this review included only observational studies, a greater level of heterogeneity was expected. Heterogeneity was tested using the χ^2 ^test and measured using the I^2^ test. Sensitivity analyses were undertaken to explore the influence of different variables on the overall estimate of effect and as potential sources of heterogeneity including specific types of infections within categories and study quality (low, moderate, high NOS score). Analysis was conducted using STATA/SE  V.12.0.

Results {#s3}
=======

The study selection process is shown in [figure 1](#F1){ref-type="fig"}. There were a total of 345 studies included, 243 CS and 102 CCS. Study characteristics and the types of infections reported in the included trials are listed in [table 1](#T1){ref-type="table"}. Most of studies were conducted in North America (55%) followed by Europe (29%). The mean age of the participants was 61 years old and ranged from 26 to 80 years. Of all infections measured in the analysis, almost 45% were SSTI, followed by RTI (9%) and genitourinary infections (8%). According to the NOS, most of the studies included were of moderate quality (score 4--6) (80.9%).

![Study selection process.](bmjdrc-2016-000336f01){#F1}

###### 

Study characteristics summary of observational studies evaluating the association between diabetes and infection

  ---------------------------------------------------------------------------------------------------------------------
  Characteristics                          CS, n=243                   CCS, n=102            Total, n=345
  ---------------------------------------- -------------------------- ---------------------- --------------------------
  **Year of study, n (%)**                                                                   

   \<1990                                  4 (1.6)                    1 (1.0)                5 (1.4)

   1990--1994                              8 (3.3)                    4 (3.9)                12 (3.5)

   1995--1999                              8 (3.3)                    12 (11.8)              20 (5.8)

   2000--2004                              33 (13.6)                  20 (19.6)              53 (15.4)

   2005--2009                              64 (26.3)                  34 (33.3)              98 (96.1)

   2010--2014                              126 (51.8)                 31 (30.4)              157 (45.5)

  Mean age (range), no. of studies         61.9 (28--80), n=172       55.9 (26--76), n=54    61.0 (26--80), n=226

  Male, n (%), no. of studies              15 576 079 (47.0), n=210   705 950 (48.0), n=76   16 282 029 (48.3), n=286

  Mean follow-up (years), no. of studies   4.4, n=70                  NA                     4.4, n=70

  **Setting, n (%)**                                                                          

   Hospital                                216 (88.9)                 85 (83.3)              301 (87.2)

   Clinic                                  18 (7.4)                   11 (10.8)              29 (8.4)

   Hospital and clinic                     8 (3.3)\                   5 (4.9)\               13 (3.8)\

   Long-term facilities                    1 (0.4)                    1 (1.0)                2 (0.6)

  **Region, n (%)**                                                                          

   Europe                                  62 (25.5)                  38 (37.2)              100 (29.0)

   Asia                                    61 (25.1)                  18 (17.6)              79 (22.9)

   North America                           111 (45.7)                 44 (43.0)              155 (44.9)

   South America                           7 (2.9)                    2 (2.0)                9 (2.6)

   Africa                                  2 (0.8)                    0 (0)                  2 (0.6)

  **Population, n (%)**                                                                      

   General population                      71 (29.2)                  54 (53.0)              125 (36.2)

   Cardiovascular disease                  72 (29.6)                  18 (17.6)              90 (26.1)

   Bone disease                            16 (6.6)                   7 (6.9)                23 (6.7)

   Kidney disease                          17 (7.0)                   4 (3.9)                21 (6.1)

   Malignancy                              14 (5.8)                   2 (2.0)                16 (4.6)

   Gastrointestinal disease                10 (4.1)                   3 (2.9)                13 (3.8)

   Spine disease                           10 (4.1)                   2 (2.0)                12 (3.5)

   Organ transplant                        7 (2.9)                    4 (3.9)                11 (3.2)

   Genitourinary disease                   8 (3.3)                    1 (1.0)                9 (2.6)

   Critically ill                          4 (1.6)                    5 (4.9)                9 (2.6)

   Pregnancy                               4 (1.6)                    0 (0)                  4 (1.2)

   Burn                                    3 (1.2)                    0 (0)                  3 (0.9)

   Ophthalmologic                          0 (0)                      2 (2.0)                2 (0.6)

   Respiratory disease                     2 (0.8)                    0 (0)                  2 (0.6)

   Obesity                                 1 (0.4)                    0 (0)                  1 (0.3)

   Breast reconstruction                   3 (1.2)                    0 (0)                  3 (0.9)

   Autoimmune disease                      1 (0.4)                    0 (0)                  1 (0.3)

  **Outcome, n (%)**                                                                         

   Not specified infections                36 (14.8)                  12 (11.8)              48 (13.9)

   Skin and soft tissue infections         114 (46.9)                 36 (35.3)              150 (43.5)

   Respiratory tract infections            17 (7.0)                   14 (13.7)              31 (9.0)

   Genitourinary infections                18 (7.4)                   11 (10.8)              29 (8.4)

   Gastrointestinal infections             1 (0.4)                    6 (5.9)                7 (2.0)

   Head and neck infections                1 (0.4)                    2 (2.0)                3 (0.9)

   Blood infections                        16 (6.6)                   10 (9.8)               26 (7.5)

   Viral infections                        7 (2.9)                    4 (3.9)                11 (3.2)

   Bone infections                         2 (0.8)                    2 (2.0)                4 (1.2)

   Other infections                        1 (0.4)                    4 (3.9)                5 (1.4)

   Multiple infections                     30 (12.3)                  1 (1.0)                31 (9)

  **NOS, n (%)**                                                                             

   Weak (score 0--3)                       0 (0)                      0 (0)                  0 (0)

   Moderate (score 4--6)                   197 (81.0)                 82 (80.4)              279 (80.9)

   Strong (score 7--9)                     46 (19.0)                  20 (19.6)              66 (19.1)
  ---------------------------------------------------------------------------------------------------------------------

CCS, case--control studies; CS, cohort studies; NA, not applicable; NOS, Newcastle-Ottawa Quality Assessment Scale. 

[Figure 2A--](#F2){ref-type="fig"}D shows the number of studies, pooled ORs, and 95% CI for our main categories of infections. Individual characteristics of included studies are present in [Appendix C](#SP2){ref-type="supplementary-material"}. Forest plots for individual studies of crude and adjusted results are shown in [Appendix D](#SP1){ref-type="supplementary-material"}.

![Pooled crude (A) and adjusted (B) OR for cohort studies and pooled crude (C) and adjusted (D) OR for case--control studies  by infection type.](bmjdrc-2016-000336f02){#F2}

Skin and soft tissue infections {#s3a}
-------------------------------

Our review found 176 studies (140 CS, 36 CCS) that evaluated the association between diabetes and SSTI ([table 2](#T2){ref-type="table"}; [Appendix D1](#SP1){ref-type="supplementary-material"}). The pooled crude OR for an SSTI from CS was 2.34 (95% CI 2.00 to 2.74; I^2^=98.8%), with a comparable pooled adjusted OR of 1.94 (95% CI 1.78 to 2.12; I^2^=92.5%). As for CCS, the crude OR was 2.90 (95% CI 2.23 to 3.78; I^2^=75.7%), and the adjusted OR was 2.64 (95% CI 2.20 to 3.17; I^2^=0%). To explore potential sources of heterogeneity between studies, we further categorized these infections to surgical site infections (SSI) and other SSTI. As shown in [table 2](#T2){ref-type="table"}, the results showed a positive association with diabetes, with decreased heterogeneity for both subgroups (SSI: crude OR 2.35, 95% CI 1.97 to 2.80, I^2^=98.9%, adjusted OR 2.03, 95% CI 1.84 to 2.25, I^2^=86.6%; other SSTI: crude OR 2.23, 95% CI 1.67 to 2.96, I^2^=91.8%, adjusted OR 1.83, 95% CI 1.74 to 1.93, I^2^=46.5%), and was less for the CCS (SSI: crude OR 3.13, 95% CI 2.37 to 4.15, I^2^=74%, adjusted OR 2.66, 95% CI 2.18 to 3.23, I^2^=0%; other SSTI: crude OR 1.69, 95% CI 1.05 to 2.72, I^2^=55.8%). SSI were further stratified according to type of surgery into nine categories.

###### 

Skin and soft tissue, respiratory and genitourinary infections

  Subgroup                          Study design   No. of studies   Crude OR (95% CI)       I^2^    No. of studies   Adjusted OR (95% CI)    I^2^
  --------------------------------- -------------- ---------------- ----------------------- ------- ---------------- ----------------------- -------
  Skin and soft tissue infections                                                                                                            
  Surgical site infections          CS             105              2.35 (1.97 to 2.80)     98.9%   56               2.03 (1.84 to 2.25)     86.6%
                                    CCS            30               3.13 (2.37 to 4.15)     74%     14               2.66 (2.18 to 3.23)     0%
  General surgery                   CS             17               2.72 (1.45 to 5.08)     99.8%   6                1.60 (1.15 to 2.23)     75%
                                    CCS            5                4.34 (1.12 to 16.89)    95.1%   2                2.11 (1.37 to 3.26)     0%
  Cardiovascular surgery            CS             44               2.20 (1.93 to 2.51)     58.5%   29               2.10 (1.86 to 2.36)     74.9%
                                    CCS            15               2.71 (2.20 to 3.33)     18.2%   7                2.76 (2.13 to 3.57)     0%
  Orthopedic surgery                CS             16               2.50 (1.90 to 3.30)     73.0%   8                1.96 (1.16 to 3.34)     74.9%
                                    CCS            4                2.45 (1.66 to 3.62)     0%      2                2.32 (1.37 to 3.94)     0%
  Spine surgery                     CS             12               2.99 (1.77 to 5.05)     87.0%   6                2.14 (1.44 to 3.18)     25.9%
                                    CCS            5                4.24 (2.57 to 7.00)     0%      3                4.15 (1.99 to 8.66)     0%
  Skin surgery                      CS             3                2.15 (0.85 to 5.41)     76.8%   3                1.51 (1.07 to 2.13)     43.3%
  Maxillofacial surgery             CS             2                2.95 (1.28 to 6.83)     83.6%   2                4.01 (1.69 to 9.54)     84.0%
  Gynecological surgery             CS             2                1.28 (0.32 to 5.13)     85.4%                    No studies identified   
  Plastic surgery                   CS             6                1.99 (1.24 to 3.18)     0%                       No studies identified   
  Ear, nose, throat surgery         CS             3                2.07 (0.80 to 5.38)     48%                      No studies identified   
  Other SSTI                        CS             14               2.23 (1.67 to 2.96)     91.8%   7                1.83 (1.74 to 1.93)     46.5%
                                    CCS            4                1.69 (1.05 to 2.72)     55.8%                    No studies identified   
  Peritonitis                       CS             4                3.66 (1.18 to 11.36)    93.3%   2                1.37 (0.95 to 1.97)     0%
  Erysipelas                        CCS            2                1.24 (0.87 to 1.75)     0%                       No studies identified   
  Respiratory tract infections                                                                                                               
  URTI                              CS                              No studies identified           1                1.18 (1.17 to 1.19)     0%
  LRTI                              CS             30               1.48 (1.33 to 1.64)     80.4%   14               1.35 (1.28 to 1.43)     79.4%
                                    CCS            12               2.01 (1.65 to 2.44)     95.6%   10               1.60 (1.35 to 1.89)     86.7%
  Tuberculosis                      CS             10               1.42 (1.23 to 1.65)     74.2%   9                1.31 (1.20 to 1.42)     60%
                                    CCS            7                2.42 (1.86 to 3.15)     95.0%   6                1.86 (1.44 to 2.41)     87.1%
  Pneumonia                         CS             19               1.51 (1.26 to 1.81)     83.8%   6                1.43 (1.36 to 1.51)     70.1%
                                    CCS            6                1.61 (1.27 to 2.04)     78.9%   4                1.26 (1.21 to 1.31)     0%
  Unspecified RTI                   CS             2                1.50 (0.56 to 4.05)     85.7%                    No studies identified   
  Genitourinary infections                                                                                                                   
  Genital infections                CS             4                2.60 (1.58 to 3.52)     85.2%   3                1.41 (1.14 to 1.74)     98.6%
  Male                              CS                              No studies identified           2                1.28 (1.01 to 1.64)     98.8%
  Female                            CS             3                1.57 (0.60 to 4.14)     89.6%   3                1.49 (1.17 to 1.91)     92.6%
  Urinary infections                CS             25               1.99 (1.79 to 2.22)     91.0%   11               1.75 (1.52 to 2.00)     99.0%
                                    CCS            9                3.06 (2.21 to 4.23)     81.2%   7                2.59 (1.60 to 4.17)     86.0%
  UTI                               CS             23               2.14 (1.75 to 2.62)     97.8%   9                1.49 (1.30 to 1.72)     98.8%
                                    CCS            8                2.98 (2.12 to 4.19)     82.7%   6                2.45 (1.48 to 4.05)     87.4%
  Renal infections                  CS                              No studies identified           2                2.40 (1.55 to 3.71)     98.4%
  Bacteriuria                       CS             3                1.94 (1.77 to 2.13)     0%      2                1.81 (1.66 to 1.97)     0%
  Unspecified GU                    CS             2                1.55 (1.11 to 2.18)     0%                       No studies identified   

CCS, case--control studies; CS, cohort studies; GU, genitourinary infection; LRTI, lower respiratory tract infection; RTI, respiratory track infection; SSTI, skin and soft tissue infection; URTI, upper respiratory tract infection; UTI, urinary tract infection. 

Respiratory tract infections {#s3b}
----------------------------

Meta-analyses of the 49 study results of RTI (CS=35, CCS=14) showed a positive association with diabetes ([table 2](#T2){ref-type="table"}; [Appendix D2](#SP1){ref-type="supplementary-material"}). For CS, the crude OR was 1.47 (95% CI 1.32 to 1.63) with considerable heterogeneity (I^2^=82.7%), and the adjusted OR was 1.35 (95% CI 1.28 to 1.43) with higher heterogeneity (I^2^=97.8%). Pooled results from CCS suggest a stronger association (crude OR 2.06 (95% CI 1.71 to 2.48; I^2^=95%); adjusted OR 1.62 (95% CI 1.37 to 1.92; I^2^=85.9%)).

Genitourinary tract infections {#s3c}
------------------------------

Thirty-three CS found a positive association between diabetes and genitourinary tract infections (crude OR 2.03 (95% CI 1.81 to 2.28, I^2^=92.4%); adjusted OR 1.61 (95% CI 1.42 to 1.82, I^2^=99.2%)) ([table 2](#T2){ref-type="table"}; [Appendix D3](#SP1){ref-type="supplementary-material"}). Similarly, pooled results from 11 control studies found genitourinary tract infections more commonly develop in people with diabetes compared with those without (crude OR 3.06 (95% CI 2.21 to 4.23, I^2^=81.2%); adjusted OR 2.59 (95% CI 1.60 to 4.17, I^2^=86.0%)).

Bloodstream infections {#s3d}
----------------------

An association was apparent between diabetes and incident bloodstream infections ([Appendices A and D4](#SP1){ref-type="supplementary-material"}). Pooled results from 31 CS (crude OR 1.82 (95% CI 1.57 to 2.12, I^2^=88.4%); adjusted OR 1.72 (95% CI 1.48 to 2.00, I^2^=94.3%)) and 10 CCS (crude OR 3.18 (95% CI 2.37 to 4.26, I^2^=72.1%); adjusted OR 2.40 (95% CI 1.68 to 3.42, I^2^=71.7%)) showed a higher chance of developing bloodstream infections for patients with diabetes compared with without.

Viral infections {#s3e}
----------------

We identified 14 studies (CS=10, CCS=4) reporting associations between diabetes and viral infections ([Appendices A and D5](#SP1){ref-type="supplementary-material"}). Pooled effect estimates from CS (crude OR 1.14 (95% CI 0.69 to 1.87, I^2^=99.1%); adjusted OR 1.29 (95% CI 1.13 to 1.46, I^2^=97.6%)) and CCS (crude OR 1.32 (95% CI 1.14 to 1.54, I^2^=89.9%)) showed a positive association.

Head and neck infections {#s3f}
------------------------

Five studies (CS=3, CCS=2) reported H&NI ([Appendices A and D6](#SP1){ref-type="supplementary-material"}). Pooled effects from CS (crude OR 1.33 (95% CI 1.08 to 1.65, I^2^=29.9%); adjusted OR 1.17 (95% CI 1.13 to 1.22, I^2^=45.4%)) and CCS (crude OR 1.55 (95% CI 0.22 to 11.10, I^2^=80.7%)) showed an association.

Gastrointestinal infections {#s3g}
---------------------------

There were four CS and six CCS that reported a gastrointestinal infection ([Appendices A and D7](#SP1){ref-type="supplementary-material"}). CS gave a (crude OR) of 1.13 (95% CI 0.86 to 1.47, I^2^=83.3%), with the (adjusted OR) of 1.48 (95% CI 1.40 to 1.57, I^2^=64.5%). However, CCS showed a stronger association with a (crude OR) of 2.44 (95% CI 1.26 to 4.71, I^2^=89.9%) and an (adjusted OR) of 3.61 (95% CI 2.94 to 4.43, I^2^=0%).

Bone infections {#s3h}
---------------

Seven studies (CS=5, CCS=2) reported bone infections ([Appendix D8](#SP1){ref-type="supplementary-material"}). Pooled results from CS showed a positive association between diabetes and bone infections (crude OR 2.40 (95% CI 1.46 to 3.94, I^2^=0%)). There were insufficient data to pool results from CCS.

Not specified infections {#s3i}
------------------------

There were 67 studies (CS=52, CCS=15) that reported infections with no specification of type as the outcome ([Appendices A and D9](#SP1){ref-type="supplementary-material"}).

We further pooled the results from high score quality studies in both CS and CCS. The results were consistent across all types of infections ([Appendix B](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Although a possible association between diabetes and risk of developing different types of infections has long been speculated,[@R13] our study provides the most extensive review to date examining the association between diabetes and incident infections. We identified 345 observational studies that reported on one or more types of infection. These studies were diverse in their source population, methods, and quality. Nonetheless, we found a positive association across all categories of infections, although the magnitude of association is variable, heterogeneity between studies is high, and the extent of evidence is vastly different for certain infections.

Our study supports the hypothesis that diabetes affects immunity leading to a higher chance of developing multiple types of infections. Indeed, our meta-analysis of adjusted results from both CS and CCS found statistically significant associations among all outcomes. These findings are supported by a large body of pathophysiological evidence across our outcomes of interest. In general, diabetes is known to affect healing,[@R23] and hyperglycemia affects coagulation, fibrinolytic function,[@R25] lipid metabolism and endothelial function.[@R26] Moreover, hyperglycemia decreases function of neutrophils and monocytes by way of impaired chemotaxis, adherence, phagocytosis and other immune system impairment.[@R5] In addition, people with diabetes are at higher risk of infections with certain microorganisms, mainly *Streptococcus* (Group A&B Streptococcus) and *Staphylococcus*.[@R28]

There are also specific factors that may predispose patients with diabetes to certain types of infections. For example, a predisposing factor for RTI may be present given patients with diabetes are often nasal carriers of *Staphylococcus aureus* and therefore may be at increased risk of associated pneumonia.[@R30] Persons with diabetes are also susceptible to pulmonary infections because of an increased risk of aspiration secondary to gastroparesis, diminished cough reflex, and disordered sleep patterns.[@R32] Impaired lung functions in these patients contribute to acquiring this type of infection as well.[@R33] The pathophysiology of lung abnormalities in patients who have diabetes is believed to involve microangiopathic changes in the basement membrane of pulmonary blood vessels and respiratory epithelium, as well as non-enzymatic glycosylation of tissue protein.[@R35]

Similarly, several factors are thought to predispose diabetic subjects to urinary tract infections.[@R20] Reduced sensitivity and altered distensibility of the urinary bladder due to autonomic neuropathy can result in stagnation of urine and higher rates of instrumentation.[@R41] Moreover, glycosuria can enhance bacterial growth and impair phagocytosis. Genital infections might be linked to diabetes through certain potential mechanisms. It is well established that yeasts thrive in a sugar-rich environment, and therefore, it is logical to hypothesize that high glucose concentrations in patients with diabetes may be responsible for promoting the occurrence and recurrence of candidiasis. *Candida albicans* virulence is shown to flourish in a hyperglycemic environment.[@R42]

Poor glycemic control can increase the incidence and accelerate the progression of periodontal disease.[@R45] The contributing factors involve higher salivary glucose, low salivary pH, microangiopathy, and abnormal collagen metabolism.[@R20]

The association between diabetes and viral infections is supported by various diabetes-specific in vitro defects in innate and adaptive immunity, and studies that showed that long-standing diabetes is often accompanied by impaired cell-mediated immunity, which increases the risk to more severe and widespread infections. This could also be the case for gastrointestinal infections and other types that were shown in the review.

Our review is not without limitations. First, a meta-analysis including observational studies is reliant on the validity of these studies; however, observational studies are methodologically challenging, difficult to interpret and susceptible to several types of bias and confounding. Furthermore, lack of uniformity of diagnosis for diabetes across studies may introduce bias. To mitigate these challenges, we used a validated scale to assess study quality wherein the majority of included studies were of moderate quality. Second, some of the included studies used self-reported assessments to identify diabetes. Self-reported measures of diabetes status have been previously shown to be over 99% specific and 66% sensitive compared with medical records.[@R50] In addition, misclassification of patients with diabetes who did not know that they had the disease to the referent group of participants without diabetes is highly likely given that 46% of the estimated prevalence of diabetes is in people with undiagnosed disease.[@R1] Third, some of the included studies were not specifically designed to quantify the association between diabetes and a particular infection or set of infections; however, the relevant data were reported to be included in our meta-analysis. In addition, although we understand the importance of presenting the relationship between the degree of glycemia and incidence of infection, hemoglobin A1C was seldom mentioned in most of the included studies. However, the degree of glucose control and antidiabetic medications use, if mentioned in the included studies, could be found under the definition of diabetes in the individual characteristics of included studies alongside other specific information as definition of infection with specific bacteriology if mentioned ([Appendix C](#SP2){ref-type="supplementary-material"}). Fourth, we recognize the limitation of having a single reviewer assessing the quality of each study. However, two independent reviewers verified data extraction. Moreover, although we do realize that most of the studies included in the review were of moderate quality, we further pooled the results of only high-quality studies to strengthen our conclusion. The results were consistent across all types of infections. Fifth, the heterogeneity in our main analyses was high. We explored heterogeneity across our results by grouping infections in several subtypes, and further grouping those into subcategories generally decreased the degree of heterogeneity. Sixth, many studies were conducted in specific clinical populations with various comorbidities present. It is possible that the association between diabetes and incident infections may be modified by the presence of certain comorbidities. Exploring effect modification was beyond the scope of this study. Lastly, we only included studies in English in our review. The reason for that is feasibility. However, our review managed to obtain a large number of studies, and others have reported that excluding non-English studies does not influence the results substantially.[@R51]

In conclusion, our extensive systematic review and meta-analysis showed that there is a positive association between diabetes and the development of several types of infection. The magnitude of the relationship varied according to type of infection. Our review identified gaps within the evidence for certain infections. More research is needed to explore the effect patient characteristics such as body mass index and glycemic control have on the risk of these types of infections.
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